A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

Amrubicin is an active and well-tolerated regimen in patients with previously treated lung cancer. Amrubicin 35 mg/m2 seems to achieve similar efficacy with less toxicity than amrubicin 40 mg/m2 in this patient population. These results warrant further evaluation in previously treated lung cancer.